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Abstract
Background: Patients with early stage papillary thyroid carcinoma (PTC), are faced with the decision to either to
accept or reject adjuvant radioactive iodine (RAI) treatment after thryroidectomy. This decision is often difficult
because of conflicting reports of RAI treatment benefit and medical evidence uncertainty due to the lack of long-
term randomized controlled trials.
Methods: We report the protocol for a parallel, 2-arm, randomized trial comparing an intervention group exposed
to a computerized decision aid (DA) relative to a control group receiving usual care. The DA explains the options
of adjuvant radioactive iodine or no adjuvant radioactive iodine, as well as associated potential benefits, risks, and
follow-up implications. Potentially eligible adult PTC patient participants will include: English-speaking individuals
who have had recent thyroidectomy, and whose primary tumor was 1 to 4 cm in diameter, with no known
metastases to lymph nodes or distant sites, with no other worrisome features, and who have not received RAI
treatment for thyroid cancer. We will measure the effect of the DA on the following patient outcomes: a)
knowledge about PTC and RAI treatment, b) decisional conflict, c) decisional regret, d) client satisfaction with
information received about RAI treatment, and e) the final decision to accept or reject adjuvant RAI treatment and
rationale.
Discussion: This trial will provide evidence of feasibility and efficacy of the use of a computerized DA in explaining
complex issues relating to decision making about adjuvant RAI treatment in early stage PTC.
Trial registration: Clinical Trials.gov Identifier: NCT01083550
Background
Thyroid cancer is increasingly being diagnosed in North
America and Europe [1-5]. Papillary thyroid carcinoma
(PTC) accounts for the majority of these newly diagnosed
cases [1,6]. Most patients diagnosed with PTC have early
s t a g ed i s e a s ea n da r ea tl o wr i s ko fd y i n gf r o mt h y r o i d
cancer [7]. It is currently recommended that most
patients with PTC undergo surgical removal of the thyr-
oid (total or near-total thyroidectomy), to be followed by
life-long thyroid hormone therapy [8-10]. Adjuvant
radioactive iodine (RAI) treatment or the option of no
adjuvant RAI treatment (with close medical follow-up)
may be offered in early stage PTC after thyroidectomy
[8,11]. There are no long-term randomized controlled
trials examining whether adjuvant RAI treatment reduces
the risk of thyroid cancer-related recurrence or mortality
in early stage PTC, and the best available observational
evidence includes conflicting reports of treatment benefit
[11]. The potential risks, benefits, reproductive consid-
erations, and implications for disease follow-up must be
considered in RAI decision making. However, in early
stage PTC, adjuvant RAI treatment decision-making is
complex and subject to some uncertainty [11].
In a recent focus group study conducted in Canada
[12], thyroid cancer survivors reported receiving conflict-
ing recommendations on adjuvant post-surgical RAI
treatment from healthcare providers and insufficient
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any medium, provided the original work is properly cited.information on rationale, risks, and uncertainties relating
to this treatment. In many cases, no choice was offered
and patients felt the treatment was imposed on them.
This lack of clarity in communication has led thyroid
cancer survivors to call for the development of plain-lan-
guage, evidence-based information on this topic, such as
in a DA [12]. Decision aids are instruments used to
inform patients about available treatment options which
have been found to generally improve general patient
knowledge, to result in more realistic patient treatment
expectations, to increase active patient participation in
decision making, and to reduce indecisiveness, when
compared to usual care; DA’s may be computerized or
paper-based or a combination of both [13].
Our aim in this randomized controlled trial, is to eval-
uate, in individuals with early stage PTC who have had
thyroidectomy, the effect of a computer-based DA on
the following outcomes: a) knowledge about PTC and
RAI treatment (primary outcome), b) decisional conflict,
c) decisional regret, d) client satisfaction with informa-
tion received about RAI treatment, and e) the final deci-
sion to accept or reject adjuvant RAI treatment and the
rationale for this decision. The comparator group will
be individuals with early stage PTC who have not been
exposed to the DA but who have received usual care
from their physicians. We present herein the protocol
that we are using to conduct this trial.
Methods
Design
In order to evaluate this DA, we propose to conduct a
single-centre, patient-level randomized controlled trial,
comparing exposure to the DA (with usual care) to a
control group of usual care. The study protocol has
been approved by the University Health Network
Research Ethics Board. Signed informed consent will be
obtained from all participants.
Setting
Administration and testing of the DA will be conducted
in a research office at the Toronto General Hospital site
of the University Health Network in Toronto, Canada.
The University Health Network is a tertiary care referral
centre for thyroid cancer care. Participants not cared for
at the University Health Network will be eligible for par-
ticipation in the trial, providing the report of their thyr-




Participants in the study will include individuals with
early stage papillary carcinoma in whom either accept-
ing or rejecting adjuvant RAI treatment are reasonable,
given the lack of clear-cut evidence guiding therapy.
Potentially eligible patient participants will include: indi-
viduals who have had complete resection of their thyr-
oid at surgery (total or near-total thyroidectomy, or
hemi- [subtotal] with completion thyroidectomy) at the
age of 18 years or older, in the time since September 1,
2009 (last thyroid surgery on or after September 1,
2009). The papillary thyroid cancer must have been of
TNM pathologic stage pT1 or pT2, N0 (or Nx), M0 (or
Mx) (TNM stage, American Joint Committee on Cancer
VI [14]) (ie. primary tumor size 1-4 cm, no known posi-
tive lymph nodes at the time of primary surgery, no
extension of the tumor outside the thyroid, no venous
or lymphatic invasion, and no known distant metastases
at primary surgery, with no tall cell features, as per sur-
gical pathology report). Individuals concurrently diag-
nosed with medullary or anaplastic or poorly
differentiated thyroid cancer or thyroid lymphoma are
not eligible for the study. Participants must be able to
communicate in spoken and written English and able to
use a computer and provide informed consent on their
own (without any need for translation). The reason for
the English language fluency criterion is that the DA is
currently available only in English.
Exclusion criteria
Individuals who have already received RAI treatment for
thyroid cancer are not eligible for this study, since the
decision to accept RAI treatment would have already
been made in such individuals. However, individuals
meeting inclusion criteria who are on the waiting list for
R A It r e a t m e n tm a yb ee l i g i b l e ,s i n c et h e i rd e c i s i o n
could still be subject to change. Participants not meeting
the inclusion criteria will be ineligible. Individuals who
have been temporarily stopped taking thyroid hormone
(for the purpose for testing or RAI treatment), will not
be eligible for the study while off this medication, since
it could potentially impact cognitive ability. Individuals
who are unwilling for investigators to confirm their
pathologic stage of thyroid cancer through review of
pathology reports, will be ineligible for the study.
Participant recruitment
Participants will be recruited through the following means:
a) review of recent pathology records reviewed at Univer-
sity Health Network, with mailing of information about
the study to potentially eligible participants, b) review of
the radioactive iodine treatment wait list at the University
Health Network, with mailing of the information about
the study to potentially eligible participants, c) use of pos-
ters and flyers about the study in University Health Net-
work (hallways, patient wait areas, and clinics), d)
dissemination of information about the study through
internet media and possibly newsletters of a Canadian
thyroid cancer support group (Thyroid Cancer Canada,
formerly known as Thry’vors), e) and distribution of
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requested) to thyroid cancer physicians in the Greater
Toronto Area. Recruitment materials will indicate that
potentially interested participants should telephone the
research office for more information. A research staff
member will then inform potential participants about the
trial and collect information on eligibility. All pathology
reports of potential participants will be reviewed for elig-
ibility by either the primary investigator (AMS) or co-
investigator (DPG). A consent form for release of medical
information will be signed by potentially eligible partici-
pants to obtain thyroid cancer surgical pathology reports
from treating physicians, if this information is not already
available to investigators nor provided by patients at
recruitment. Patient participants will be compensated with
$100 after completion of the first study visit (randomiza-
tion and testing) and with an additional $100 for comple-
tion of the telephone follow-up.
Intervention
Decision aid
A multi-disciplinary team of thyroid cancer physicians
and methodologists were involved in development of the
computerized DA. The content of the DA was based on
the information needs identified by thyroid cancer survi-
vors in a focus group study [12] and the physician mem-
bers involved in development. Multiple systematic
reviews of the literature were conducted in order to
ensure the DA content was evidence-based [11,15-17].
The DA was subjected to pre-testing by thyroid cancer
physicians, thyroid cancer survivors, and lay individuals
(usability testing followed by revisions).
For participants randomized to the intervention group,
the DA website will be opened for the participant by staff
and the participant will be asked to self-navigate the web-
site. The number of computer mouse clicks used to
retrieve information and the duration of DA examination
will be recorded for each participant in the intervention
group. It will be suggested to the participant that he or
she may spend up to 60 minutes reviewing the website,
but he or she may finish early if desired. The participant
will review the information in the DA on his or her own
during one visit at the Toronto General Hospital, with no
access to the website nor print-outs allowed at home. A
research assistant will be present in the same room dur-
ing the study visit, in case the participant has any ques-
tions about navigation of the DA. All participants in the
intervention group will receive usual care from their
treating physicians.
Usual care control group
The usual care control group will be provided counsel-
ling and care from their own treating physicians, and
not provided any exposure to the DA during the trial.
Randomization
Central computerized randomization will be performed
in a 1:1 ratio (variable block sizes) at a patient partici-
pant level. The randomization will be to the intervention
group (exposure to the computerized DA in addition to
usual care) or control group (no exposure to the DA,
only usual care). The randomization will be achieved
through the DA program, after the study staff enters the
participant’s unique identifier number, to be immedi-
ately followed by testing. Allocation will be concealed
until the this testing visit. Thus, prior to the testing
visit, neither the participant, study staff, investigators,
nor treating physicians will be aware of the allocation.
Outcomes, follow-up, and data collection
Participant involvement in the trial will include one visit
to the Toronto General Hospital, at which point, signed
informed consent for participation in the trial will be
obtained, and baseline data will be collected on demo-
graphic characteristics and psychological coping style
[18]). The randomization will be performed, and the
intervention administered at this time (for those rando-
mized to the DA group), and self-administered ques-
tionnaires will be completed. A telephone follow-up
interview will be performed at 6 months (with telephone
follow-up in subsequent months, after the decision on
RAI treatment has been finalized).
To assess efficacy of the DA intervention, the primary
outcome measured in thist r i a lw i l lb et h es c o r e
(number of correct responses out of 10 questions) on a
self-administered written questionnaire examining
knowledge about PTC and RAI treatment, which will be
administered at the randomization visit (immediately
after exposure to the DA in the intervention group, or
after revealing no exposure to the DA in the control
group). After the knowledge questionnaire is completed,
decisional conflict [19,20] relating to the decision to
accept or reject adjuvant RAI treatment will be assessed
as a secondary outcome, using a self-administered ques-
tionnaire in all participants.
Telephone follow-up will be performed six months
after the randomization visit for all participants. If, the
final decision on RAI treatment has not been finalized
by this time (ie. decision not yet made, or if the partici-
pant is on a waiting list for RAI treatment but has not
yet received it), another telephone follow-up will be set
up within the next several months (depending on timing
of any planned RAI treatment or finalization of the deci-
sion). The following data will be collected by telephone
interview 6 months after randomization: a follow-up
interview on RAI decision-making (inquiring about the
final decision about RAI treatment and rationale), a cli-
ent satisfaction questionnaire on information received
relating to RAI decision-making (modified from general
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Style Scale, MBSS, [21]]), and a decision regret question-
naire [22,23]. If, at the 6-month follow-up phone call,
the final decision on RAI treatment has not been fina-
lized, the decisional regret questionnaire will be deferred
until another telephone call to be set up in subsequent
months (after finalization of the treatment decision). If a
second telephone follow-up call is required, the inter-
view questions and questionnaires administered at 6
months will be repeated.
Statistical considerations
Quantitative analysis
For descriptive analyses, categorical data will be
expressed as number and proportion (or percentage),
whereas continuous data will be expressed as mean and
standard deviation (or median and range). Independent
sample t-tests will be used to compare questionnaire
scores, using an intention-to-treat principle. A chi-
squared analysis will be used to compare the proportion
of individuals accepting RAI treatment in the interven-
tion group compared to the control group (separate
analyses for all participants, as well as excluding those
on the radioactive iodine treatment wait list at the time
of recruitment). Alpha = 0.05 will be used as the cut-off
for statistical significance for all analyses. Missing data
for any questionnaire subscales will be imputed from
the mean of the rest of the questions within that sub-
scale, for questionnaires in which subscales are
established.
Qualitative analysis
Content analysis of the qualitative data collected in the
telephone follow-up (including the decision to accept or
reject RAI treatment and rationale), will be completed
manually, using the notes of the telephone interviewer.
The major themes will be identified using grounded the-
ory [24-26]. Descriptive frequency analysis of coded data
will also be quantified using mixed methods [27-29].
Sample size calculations
The sample size is calculated to detect a one point dif-
f e r e n c ei nt h em e a ns c o r eo ft h ek n o w l e d g eq u e s t i o n -
naire (relating to PTC and RAI treatment), between the
intervention and usual care groups, assuming a standard
deviation of 1.5 (Power and Precision software, Biostat,
Inc., Englewood, NJ, USA). The intended sample size is
37 individuals per group (total of 74) (0.05 2-tailed
alpha, power 0.808).
Additional exploratory analyses
We will examine the following Spearman correlation
coefficients for the baseline monitoring and blunting
coping questionnaires scores (as measured by the
MBSS) relative to the following: a) number of computer
mouse clicks used by individuals in the intervention
group to retrieve information within the DA, b) knowl-
edge questionnaire score, c) and participant satisfaction
with information received, as assessed at telephone fol-
l o w - u p .W ew i l la l s oc o m p a r et h eM B S Ss c o r e si ni n d i -
viduals who ultimately receive adjuvant RAI treatment
compared to those who reject it (Student’s t-tests).
Invitation for feedback from treating physicians
In the months before study completion, we will mail out
a self-administered written satisfaction survey (modified
from general questionnaire on client satisfaction [20]) to
thyroid physicians and surgeons in active practice at the
University Health Network (where the majority of
patient participants are expected to be recruited). This
survey will invite physicians’ feedback on their experi-
ence with patients who may have been exposed to the
DA intervention in the trial.
Knowledge translation plan
After completing testing of the proposed DA and publi-
cation of the results of this study, it is planned for the
decision aid to be made publicly available on the website
o ft h eU n i v e r s i t yH e a l t hN e t w o r kP a t i e n tE d u c a t i o n
Network website, such that it can be made available to
PTC patients and treating physicians at UHN, other aca-
demic centres, and the community. We will also be
Decision aid 
(plus usual care) 
Usual care 
(no decision aid) 
Consenting individuals with early stage PTC meeting eligibility criteria 
Randomization/Study Visit at University Health Network 
Questionnaires filled out by all participants will include the following: 
1) Demographic  questionnaire 
2) Miller  Behavioral  Style  Scale 
3)  Knowledge Questionnaire on PTC and RAI treatment*
4) Decisional  Conflict  Questionnaire*
(*administration post-decision aid in the intervention group) 
Telephone follow-up at 6 months + after RAI treatment decision finalized  
(Telephone call after 6 months only if RAI decision not finalized at 6 months) 
1)  Follow-up interview inquiring about decision to accept or reject RAI treatment and 
rationale for the decision 
2)  Client satisfaction with information on radioactive iodine questionnaire 
3)  Decision Regret questionnaire (only after RAI decision finalized) 
Invitation to thyroid cancer physicians at University Health Network for feedback 
In the months study completion, a mail-out survey will be sent to physicians and 
surgeons treating thyroid cancer at University Health Network, inquiring about physician 
satisfaction with patients’ exposure to the decision aid 
Figure 1 Overview of the study. PTC: papillary thyroid cancer, RAI:
radioactive iodine.
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support group (Canadian Thyroid Cancer Canada, for-
merly known as Thry’vors), and sharing links to the DA
website if the group is interested.
Discussion
We have presented the design of a randomized con-
trolled trial to evaluate the effect of a decision aid,
explaining the options of adjuvant RAI treatment or no
adjuvant RAI treatment, for individuals with early stage
PTC. In particular we are interested in determining
whether the DA may improve patient knowledge about
PTC and RAI treatment, reduce decisional conflict and
decisional regret, and influence treatment choice or
rationale, as compared to usual care. The DA in ques-
tion is unique in that it explains in detail, the current
uncertainty relating to potential treatment benefits of
adjuvant RAI treatment in early stage PTC.
Abbreviations
PTC: (papillary thyroid cancer); RAI: (radioactive iodine treatment); DA:
(decision aid).
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